Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UK Favors Post-Brexit EMA/MHRA ‘Mutual Recognition’ Deal

Executive Summary

Jeremy Hunt, the UK Secretary of State for Health, has told a parliamentary committee that the EMA is likely to leave the UK but that his government will be seeking a close relationship with the agency that could involve the mutual recognition by the UK regulator of EU drug approvals.

You may also be interested in...



‘Virtually Bribery And Corruption Free’ Denmark With Its Clean Canals Says ‘Give Us EMA’

The UK is on track to start formal EU exit negotiations in March, Denmark has announced its official candidacy to host the European Medicines Agency post-Brexit, and details are emerging on the campaigns that other contenders for the EMA, such as Ireland and Italy, are waging.

Dutch Call For Early Decision On Location Of EMA And Say ‘Why Not Us?’

The Dutch government says it is well placed to host the European Medicines Agency, citing good travel links, the ability to host international organizations, and the prospect of continuity of the agency’s work. It wants a decision to be taken soon on the EMA’s future location.

Brexit: EMA Could Lose Up To Half Its Staff If It Has To Move

The European Medicines Agency is working to ensure it can cope with the many challenges it will face as a result of the UK leaving the EU. Those challenges could include the agency losing 50% of its staff, according to the EMA’s deputy head Noel Wathion.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1131867

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel